top of page
  • Recruiting

NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

Updated: Oct 23, 2022

STOMP


Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

stomp study selinexor xkd

STOMP

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM).


Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)


Sponsor

Karyopharm Therapeutics Inc

 

ClinicalTrials.gov Identifier: NCT02343042